肾透明细胞癌合并多发性骨髓瘤1例并文献复习

doi:10.3969/j.issn.1004-583X.2024.11.010

摘要/Abstract

摘要：

目的探讨肾透明细胞癌合并多发性骨髓瘤的临床特点及共同治疗的基础及可能性。方法选取河北医科大学第三医院血液科住院患者1例,回顾性分析其临床资料。结果患者男性, 52岁, 右肾癌术后2.5年,出现腰痛,完善相关检查检验证实肾透明细胞癌合并多发性骨髓瘤,此例患者在制定多发性骨髓瘤治疗方案时兼顾了肾透明细胞癌的治疗,应用了含硼替佐米、来那度胺(沙利度胺的作用类似物和升级品)的诱导方案加来那度胺维持治疗,经治疗后,目前患者随访两种肿瘤病情稳定。结论肾透明细胞癌与多发性骨髓瘤有共同的致病通路,存在共同治疗的可能性。

关键词: 癌, 肾细胞, 多发性骨髓瘤, 治疗

Abstract:

Objective To investigate the clinical features of clear cell renal cell carcinoma (ccRCC) combined with multiple myeloma (MM), and the basis and possibility of co-treatment. Methods The clinical data of one patient in the Hematology Department of Hebei Medical University Third Hospital were analyzed retrospectively.Results A 52-year-old male developed low back pain 2.5 years after the operation of ccRCC, and diagnosed as ccRCC combined with MM by a series examination. Treatment plan incorporated both ccRCC and MM. Induction regimen containing bortezomib and lenalidomide (analogs and upgraded versions of thalidomide) and maintenance therapy with lenalidomide were given, yielding a stable condition of both ccRCC and MM during the follow-up period. Conclusion ccRCC shares a common pathogenic pathway with MM. There may have a basis for the co-treatment of ccRCC and MM.

Key words: carcinoma, renal cell, multiple myeloma, treatment

中图分类号:

王家琪, 孟建波, 宋晓宁, 张金巧, 藏美蓉, 卢佳配, 锁静. 肾透明细胞癌合并多发性骨髓瘤1例并文献复习[J]. 临床荟萃, 2024, 39(11): 1021-1025.

Wang Jiaqi, Meng Jianbo, Song Xiaoning, Zhang Jinqiao, Zang Meirong, Lu Jiapei, Suo Jing. Clear cell renal cell carcinoma combined with multiple myeloma: A case report and literature review[J]. Clinical Focus, 2024, 39(11): 1021-1025.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2024.11.010

https://huicui.hebmu.edu.cn/CN/Y2024/V39/I11/1021

图/表 4

图1 骨髓象示多发性骨髓瘤象(HE染色×100)

Fig. 1 Bone marrow image visualizing the sign of multiple myeloma (H&E staining, magnification ×100)

图2 骨髓活检病理证实浆细胞肿瘤(HE及PAS染色×100),免疫组化Kappa(+)、Lambda(-)

Fig. 2 H&E and PAS staining of bone marrow biopsy pathologically confirmed plasma cell tumors; Immunohistochemistry visualizing Kappa (+) and Lambda (-) (magnification ×100)

图3 腰1椎体肿物病理(HE染色×100),证实转移性透明细胞肾细胞癌,合并浆细胞肿瘤,免疫组化Kappa(+)、Lambda(-)

Fig 3 H&E staining of L1 mass confirmed metastatic ccRCC with plasma cell tumor; Immunohistochemistry visualizing Kappa (+) and Lambda (-) (magnification ×100)

图4 化疗后骨髓细胞涂片(HE染色×100)

Fig 4 H&E staining of bone marrow smear after chemotherapy (magnification ×100)

参考文献 31

[1]	Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: A retrospective cohort study[J]. BMC Cancer, 2011, 11:83. doi: 10.1186/1471-2407-11-83 pmid: 21342533
[2]	Narwal A, Ramteke P, Kumar L, et al. Renal cell carcinoma concomitant with multiple myeloma[J]. J Pathol Transl Med, 2022, 56(2):111-112. doi: 10.4132/jptm.2022.01.21 pmid: 35306777
[3]	王天钰, 杨敏. 多发性骨髓瘤合并肾透明细胞癌一例[J]. 海南医学, 2021, 32(16):2168-2170.
[4]	Padhi S, Mokkappan S, Varghese RG, et al. Plasmablastic multiple myeloma following clear cell renal cell carcinoma[J]. BMJ Case Rep, 2014, 2014:bcr2014204778.
[5]	Choueiri TK, Baz RC, McFadden CM, et al. An association between renal cell carcinoma and multiple myeloma: A case series and clinical implications[J]. BJU Int, 2008, 101(6):712-715. pmid: 17970789
[6]	Shields LB, Kalebasty AR. Concurrent renal cell carcinoma and hematologic malignancies: Nine case reports[J]. World J Clin Oncol, 2020, 11(8):644-654. doi: 10.5306/wjco.v11.i8.644 pmid: 32879850
[7]	Padhi S, Varghese RG, Ramdas A. Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review[J]. Indian J Med Paediatr Oncol, 2013, 34(4):283-291.
[8]	杨彦, 潘志兰, 张志敏. 多发性骨髓瘤患者骨髓细胞周期素D1、D3、p21的表达及与预后的相关性研究[J]. 微循环学杂志, 2021, 31(3):58-62.
[9]	马悦, 李亚, 宫经新, 等. CyclinD1及p27蛋白在多发性骨髓瘤骨髓活检中的表达及临床意义[J]. 河北医药, 2013, 35(23):3537-3539.
[10]	陈娟, 徐永刚, 姜亚卓. Cyclin D1在肾细胞癌中的表达及其意义[J]. 现代泌尿外科杂志, 2013, 18(4):332-334.
[11]	Ozturk MA, Dane F, Kaygusuz I, et al. Synchronous renal cell carcinoma and multiple myeloma: Report of two cases and review of the literature[J]. J BUON, 2009, 14(3):511-514. pmid: 19810147
[12]	Sargın G, Yavasoglu I, Doger FK, et al. A coincidence of renal cell carcinoma and hematological malignancies[J]. Med Oncol, 2012, 29(5):3335-3338. doi: 10.1007/s12032-012-0316-7 pmid: 22843308
[13]	王霞, 孟玉莲, 顿晓熠. IL-6相关信号通路靶向药物治疗多发性骨髓瘤的研究进展[J]. 巴楚医学, 2022, 5(3):110-113.
[14]	钟雯婷, 王清水, 黄义德, 等. IL-6细胞因子家族在肾细胞癌中的研究进展[J]. 福建轻纺, 2023, (2):25-28.
[15]	辉红蕾, 周晋宇, 段秋婷, 等. 多发性骨髓瘤的信号通路及其靶向治疗的研究进展[J]. 现代肿瘤医学, 2022, 30(10):1902-1906.
[16]	吕毅, 罗志刚. 核转录因子-κB与肾癌的研究进展[J]. 临床合理用药杂志, 2014, 7(5):171-172.
[17]	Sun J, Chen F, Wu G. Role of NF-κB pathway in kidney renal clear cell carcinoma and its potential therapeutic implications[J]. Aging (Albany NY), 2023, 15(20):11313-11330.
[18]	董喜凤, 宋强, 邵宗鸿. VEGF及其受体在多发性骨髓瘤发病机制中的作用及临床意义[J]. 药品评价, 2012, 9(12):4-9.
[19]	姜春霞. 肾细胞癌组织中VEGF和PDGF的表达[J]. 肿瘤基础与临床, 2015, 28(6):480-482.
[20]	Ojha RP, Evans EL, Felini MJ, et al. The association between renal cellcarcinoma and multiple myeloma: Insights from population-based data[J]. BJU Int, 2011, 108(6):825-830.
[21]	Tzeng HE, Lin CL, Tsai CH, et al. Time trend of multiple myeloma and associated secondary primary malignancies in Asian patients: A Taiwan population-based study[J]. PLoS One, 2013, ;8(7):e68041.
[22]	Amato RJ. Thalidomide therapy for renal cell carcinoma[J]. Crit Rev Oncol Hematol, 2003, 46 Suppl:S59-65.
[23]	江炜, 罗萍. 来那度胺治疗多发性骨髓瘤的临床疗效及其安全性[J]. 临床合理用药杂志, 2021, 14(21):30-32.
[24]	姜文华, 姜达. 沙利度胺对人肾癌细胞增殖及碱性成纤维细胞生长因子表达的影响[D]. 石家庄: 河北医科大学, 2007.
[25]	Yao X, Hong JH, Nargund AM, et al. PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma[J]. Nat Cell Biol, 2023, 25(5):765-777. doi: 10.1038/s41556-023-01122-y pmid: 37095322
[26]	Amato RJ, Hernandez-McClain J, Saxena S, et al. Lenalidomide therapy for metastatic renal cell carcinoma[J]. Am J Clin Oncol, 2008, 31(3):244-249.
[27]	Patel PH, Kondagunta GV, Schwartz L, et al. Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma[J]. Invest New Drugs, 2008, 26(3):273-276.
[28]	Hov H, Tian E, Holien T, et al. c-Met signaling promotes IL-6-induced myeloma cell proliferation[J]. Eur J Haematol, 2009, 82(4):277-287. doi: 10.1111/j.1600-0609.2009.01212.x pmid: 19187270
[29]	Padhi S, Sahoo PK, Banerjee D, Ghosh RN. Renal cell carcinoma and plasma cell myeloma: Unique association and clinical implications[J]. Urol Ann, 2014, 6(3):252-256. doi: 10.4103/0974-7796.134292 pmid: 25125903
[30]	Wang Y, Suarez ER, Kastrunes G, et al. Evolution of cell therapy for renal cell carcinoma[J]. Mol Cancer, 2024, 23(1):8. doi: 10.1186/s12943-023-01911-x pmid: 38195534
[31]	徐丽秀, 倪伟建, 王伟, 等. m6A甲基化修饰在肾细胞癌中的研究进展[J]. 安徽医科大学学报, 2023, 58(12):2159-2164.